Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Identifying new therapeutic targets on the surfaceome of myeloma plasma cells with proteomics

Arun Wiita • 26 Aug 2022
IMS 2022
Multiple Myeloma

Arun Wiita, MD, PhD, University of California, San Francisco, CA, talks on the use of proteomic technologies to identify novel immunotherapeutic targets to treat multiple myeloma and to find biomarkers of resistance to immunotherapy. Dr Wiita notably mentions CCR10, a chemokine receptor that was found to be uniformly highly expressed on myeloma plasma cells. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Arun Wiita

1:37
Addressing proteasome inhibitor resistance in multiple myeloma in the immunotherapy era
Arun Wiita • 29 Sep 2023
1:15
The importance of proteomics in myeloma and how this may be implemented in clinical practice
Arun Wiita • 29 Sep 2023
1:46
Insights into mass spectrometry-based proteomics in multiple myeloma research
Arun Wiita • 29 Sep 2023
2:29
The impact of allosteric HSP70 inhibitors on proteasome inhibitor resistance in multiple myeloma
Arun Wiita • 26 Sep 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals